Celgene (CELG) is the only large-cap biotech that provides investors with long-range financial guidance. It’s a risky strategy that pays off well when the business is humming but can backfire quickly if plans run off the rails.
The latter just happened to Celgene. A weaker outlook for several of its drugs plus one big pipeline blowup forced Celgene to make a deep cut in its 2020 revenue guidance on Thursday.
About the Author Reprints
http://alphastreet.com/b0662389 Chaos continues for Celgene. Apart from the reduced outlook, a decrease in pharma company’s research and development expenses is not a good sign.